Curasight
Curasight to present at HC Andersen Capital
The presentations will include an update on the business progress made by the company during the first three quarters of 2025 and look ahead at the expected coming news flow.
Management will give an overall update on the company's pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain cancer, besides the newly reported green light for enrolling patients in the phase I trial with using uTREAT® in brain cancer, and its impact for the clinical development strategy for the coming year.
The HC Andersen Capital presentation will be webcasted live 14:00 - 14:30 (CET), Monday 1 December 2025 focusing on the brain cancer study.
An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight's website, after the presentation is completed.
For more information - please click here
| Datum | 2025-11-28, kl 11:09 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!